Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Grace Callagy"'
Autor:
Timothy B. Fisher, Geetanjali Saini, T. S. Rekha, Jayashree Krishnamurthy, Shristi Bhattarai, Grace Callagy, Mark Webber, Emiel A. M. Janssen, Jun Kong, Ritu Aneja
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-13 (2024)
Abstract Background Pathological complete response (pCR) is associated with favorable prognosis in patients with triple-negative breast cancer (TNBC). However, only 30–40% of TNBC patients treated with neoadjuvant chemotherapy (NAC) show pCR, while
Externí odkaz:
https://doaj.org/article/9bc17a375e25468388fa164cf619ad20
Autor:
Mohamed Zaakouk, Cecily Quinn, Elena Provenzano, Clinton Boyd, Grace Callagy, Soha Elsheikh, Joe Flint, Rebecca Millican-Slater, Anu Gunavardhan, Yasmeen Mir, Purnima Makhija, Silvana Di Palma, Susan Pritchard, Bruce Tanchel, Emad Rakha, Nehal M. Atallah, Andrew H.S. Lee, Sarah Pinder, Abeer M. Shaaban
Publikováno v:
Breast, Vol 70, Iss , Pp 82-91 (2023)
Background: Recent clinical evidence showed that breast cancer with low HER2 expression levels responded to trastuzumab deruxtecan therapy. The HER2-low cancers comprise immunohistochemistry (IHC) score 1+ and 2+ ISH non-amplified tumours, currently
Externí odkaz:
https://doaj.org/article/464b369375de4cabbec57321f8b22a03
Autor:
Mohamed Zaakouk, Mieke Van Bockstal, Christine Galant, Grace Callagy, Elena Provenzano, Roger Hunt, Corrado D’Arrigo, Nahla M. Badr, Brendan O’Sullivan, Jane Starczynski, Bruce Tanchel, Yasmeen Mir, Paul Lewis, Abeer M. Shaaban
Publikováno v:
Cancers, Vol 15, Iss 5, p 1511 (2023)
The assessment of PD-L1 expression in TNBC is a prerequisite for selecting patients for immunotherapy. The accurate assessment of PD-L1 is pivotal, but the data suggest poor reproducibility. A total of 100 core biopsies were stained using the VENTANA
Externí odkaz:
https://doaj.org/article/27a17d2016884714bb625c2b02f31043
Autor:
Bálint Cserni, Darren Kilmartin, Mark O’Loughlin, Xavier Andreu, Zsuzsanna Bagó-Horváth, Simonetta Bianchi, Ewa Chmielik, Paulo Figueiredo, Giuseppe Floris, Maria Pia Foschini, Anikó Kovács, Päivi Heikkilä, Janina Kulka, Anne-Vibeke Laenkholm, Inta Liepniece-Karele, Caterina Marchiò, Elena Provenzano, Peter Regitnig, Angelika Reiner, Aleš Ryška, Anna Sapino, Elisabeth Specht Stovgaard, Cecily Quinn, Vasiliki Zolota, Mark Webber, Sharon A. Glynn, Rita Bori, Erika Csörgő, Orsolya Oláh-Németh, Tamás Pancsa, Anita Sejben, István Sejben, András Vörös, Tamás Zombori, Tibor Nyári, Grace Callagy, Gábor Cserni
Publikováno v:
Cancers, Vol 15, Iss 4, p 1199 (2023)
Tumour-infiltrating lymphocytes (TILs) reflect antitumour immunity. Their evaluation of histopathology specimens is influenced by several factors and is subject to issues of reproducibility. ONEST (Observers Needed to Evaluate Subjective Tests) helps
Externí odkaz:
https://doaj.org/article/b5737028920b4e1fa44a2db009fed358
Publikováno v:
Cancer Research. 83:P4-08
Human endogenous retrovirus K (HERV-K) belongs to a family of endogenous retroviruses that are present in our genome with similarities to present day exogenous retroviruses. This virus can express several proteins but our knowledge of HERV-K expressi
Autor:
Gábor Cserni, Cecily M. Quinn, Maria Pia Foschini, Simonetta Bianchi, Grace Callagy, Ewa Chmielik, Thomas Decker, Falko Fend, Anikó Kovács, Paul J. van Diest, Ian O. Ellis, Emad Rakha, Tibor Tot, European Working Group for Breast Screening Pathology
Publikováno v:
Cancers, Vol 13, Iss 22, p 5694 (2021)
Triple-negative breast cancers (TNBC), as a group of tumours, have a worse prognosis than stage-matched non-TNBC and lack the benefits of routinely available targeted therapy. However, TNBC is a heterogeneous group of neoplasms, which includes some s
Externí odkaz:
https://doaj.org/article/16138480a83a426f85f5aec622bb0733
Autor:
Sharon A Glynn, Dibyangana Bhattacharyya, Shauna Lambe, Emma Kerr, Simon McDade, Faizan H Khan, Eoin Dervan, Feng Wang-Johanning, Sean Hynes, Grace Callagy
Publikováno v:
Cancer Research. 82:P3-06
Background: Human endogenous retrovirus K (HERV-K) belongs to a family of endogenous retroviruses that are present in our genome with similarities to present day exogenous retroviruses. HERV-K, like other endogenous retroviruses, is transmitted verti
Autor:
Ayaka Katayama, Jane Starczynski, Michael S Toss, Abeer M Shaaban, Elena Provenzano, Cecily M Quinn, Grace Callagy, Colin A Purdie, Rebecca Millican‐Slater, David Purnell, Leena Chagla, Tetsunari Oyama, Sarah E Pinder, Steve Chan, Ian Ellis, Andrew H S Lee, Emad A Rakha
Publikováno v:
Histopathology. 81:511-519
Chromosome 17 alterations affect the assessment of HER2 gene amplification in breast cancer (BC), but its clinical significance remains unclear. This study aimed to identify the prevalence of centromere enumeration probe 17 (CEP17) alterations, and i
Autor:
Darren Kilmartin, Mark O’Loughlin, Xavier Andreu, Zsuzsanna Bagó-Horváth, Simonetta Bianchi, Ewa Chmielik, Gábor Cserni, Paulo Figueiredo, Giuseppe Floris, Maria Pia Foschini, Anikó Kovács, Päivi Heikkilä, Janina Kulka, Anne-Vibeke Laenkholm, Inta Liepniece-Karele, Caterina Marchiò, Elena Provenzano, Peter Regitnig, Angelika Reiner, Aleš Ryška, Anna Sapino, Elisabeth Specht Stovgaard, Cecily Quinn, Vasiliki Zolota, Mark Webber, Davood Roshan, Sharon A. Glynn, Grace Callagy
Publikováno v:
Cancers, Vol 13, Iss 17, p 4410 (2021)
Stromal tumour infiltrating lymphocytes (sTILs) are a strong prognostic marker in triple negative breast cancer (TNBC). Consistency scoring sTILs is good and was excellent when an internet-based scoring aid developed by the TIL-WG was used to score c
Externí odkaz:
https://doaj.org/article/000cc0d867314f44ae8d89acc4df4feb
Autor:
Emad A Rakha, Puay Hoon Tan, Cecily Quinn, Elena Provenzano, Abeer M Shaaban, Rahul Deb, Grace Callagy, Jane Starczynski, Andrew H S Lee, Ian O Ellis, Sarah E Pinder
Publikováno v:
Journal of clinical pathology.
The last UK breast cancer (BC) human epidermal growth factor receptor 2 (HER2) testing guideline recommendations were published in 2015. Since then, new data and therapeutic strategies have emerged. The American Society of Clinical Oncology (ASCO)/Co